Literature DB >> 29934978

Accuracy of the HPV status site-specific factor 10 (SSF-10) variable for patients with oropharyngeal cancers in the Iowa Cancer Registry, 2010-2014.

Amanda R Kahl1, Mary E Charlton1, Nitin A Pagedar2, Steven M Sperry2, Bobbi Matt1, Charles Platz1, Charles F Lynch1.   

Abstract

BACKGROUND: Surveillance, Epidemiology, and End Results Cancer Registries (SEER) began collecting human papillomavirus (HPV) status for upper aerodigestive tract cancers in 2010. However, classification of p16-testing was not included in the Collaborative Stage coding guidelines, potentially leading to inconsistent coding.
METHODS: The HPV values for Iowa patients with oropharyngeal cancers (n = 824) were recoded based on modified guidelines that included p16 test results, and compared with the original guidelines.
RESULTS: Forty percent of patients were recoded to a different value, and the HPV testing rate increased from 45% to 55%; 56% received p16-testing only. Of those originally coded as HPV-type 16 (n = 187), 89% were recoded to HPV-not otherwise specified (NOS). When comparing high-level positive/negative/not done categories, original coding captured 81% of patients with HPV-positive cancers.
CONCLUSION: p16 was the most common HPV test but was inconsistently coded as HPV-testing. p16-positivity was also erroneously equated with HPV-type 16. Adding a separate p16 variable would improve consistency and accuracy of HPV coding.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC) staging; Surveillance, Epidemiology, and End Results (SEER); head and neck cancer; human papillomavirus (HPV)-related cancer; oropharyngeal cancer

Mesh:

Substances:

Year:  2018        PMID: 29934978      PMCID: PMC6197903          DOI: 10.1002/hed.25314

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

2.  Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.

Authors:  Arya Amini; Jagar Jasem; Bernard L Jones; Tyler P Robin; Jessica D McDermott; Shilpa Bhatia; David Raben; Antonio Jimeno; Daniel W Bowles; Sana D Karam
Journal:  Oral Oncol       Date:  2016-03-12       Impact factor: 5.337

3.  Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience.

Authors:  Aatur D Singhi; William H Westra
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

Review 4.  Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing.

Authors:  Max Robinson; Philip Sloan; Richard Shaw
Journal:  Oral Oncol       Date:  2010-03-12       Impact factor: 5.337

5.  Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

Authors:  Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

6.  Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.

Authors:  William M Lydiatt; Snehal G Patel; Brian O'Sullivan; Margaret S Brandwein; John A Ridge; Jocelyn C Migliacci; Ashley M Loomis; Jatin P Shah
Journal:  CA Cancer J Clin       Date:  2017-01-27       Impact factor: 508.702

Review 7.  p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.

Authors:  James S Lewis
Journal:  Head Neck Pathol       Date:  2012-07-03

8.  Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials.

Authors:  Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison
Journal:  Am J Surg Pathol       Date:  2012-07       Impact factor: 6.394

9.  p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer.

Authors:  Markus Hoffmann; Anna Sophie Ihloff; Tibor Görögh; Jan B Weise; Asita Fazel; Matthias Krams; Werner Rittgen; Elisabeth Schwarz; Tomas Kahn
Journal:  Int J Cancer       Date:  2010-10-01       Impact factor: 7.396

  9 in total
  3 in total

1.  Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis.

Authors:  Jennifer A Schlichting; Nitin A Pagedar; Catherine Chioreso; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2019-05-22       Impact factor: 2.506

2.  Prognostic role of human papilloma virus status in hypopharyngeal squamous cell carcinoma.

Authors:  Deborah C Marshall; Derek D Kao; Richard Bakst; Sonam Sharma; Rocco Ferrandino; Kenneth Rosenzweig; Juan Wisnivesky; Keith Sigel
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-08-11

3.  Prognostic Impact of Metastatic Site and Pattern in Patients with Metastatic Head and Neck Cancer.

Authors:  Craig A Bollig; Christopher I Newberry; Tabitha L I Galloway; Robert P Zitsch; Elyse K Hanly; Vivian L Zhu; Nitin Pagedar; Rohit Nallani; Andres M Bur; William C Spanos; Jeffrey B Jorgensen
Journal:  Laryngoscope       Date:  2020-10-24       Impact factor: 3.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.